Rabbit Anti-Presenilin 1 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Plastin L Monoclonal Antibody, Unconjugated, Clone LPL4A.1 from Abcam
...ast Cells are designed for use with the ProQuest T...MaV203 contains deletions in the endogenous GAL4 a...systems. The strain also has leu2 and trp1 mutatio.... MaV203 contains three GAL4 inducible reporter ge...
Feline IL-2 ELISpot Kit from R&D Systems
Biology Products:(Date:11/30/2009)...FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasda...s of platinum-based anti-tumor compounds, termed b...potency and activity compared to currently availab... to overcome cisplatin-resistance in cancer cell l...d "Novel Bis-platinum Complexes Endowed with an Im...
(Date:11/30/2009)...DAM, November 30 Elsevie...dical and technical products and services,today a...nsive biomedical,database which holds over 20 mill...eer reviewed journals. , Embase has long ...ical,and pharmaceutical insights. Now, new develop...
(Date:11/27/2009)...FirstCall/ -- Stallergenes has been,granted Europe...d children,through a Mutual Recognition Procedure....een marketed, was the reference Member state. ,...lgium, Bulgaria, Cyprus, the,Czech Republic, Eston...ly,Latvia, Lithuania, Luxembourg, Malta, the Neth...
(Date:11/25/2009)...-- Biotech firm Replikins Ltd., which has analyzed...ic through the prediction, outbreak, and progress ...est biochemical analysis of the virus. The new dat...") virus has dropped from its peak of 3.7 (s.d. 4....ng of 2009 to resting non-epidemic levels this wee...
Breaking Biology Technology:New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5